
First allogeneic cancer immunotherapy hits market
On December 20th, the European Commission approved Tabelecleucel (EbvalloTM) as a monotherapy for the treatment of adult and paediatric patients who...

AMsilk scaling up through Evonik collaboration
Just one week after AMSilk inked a collaboration agreement on protein engineering of its silk protein to target new applications with Brain Biotech...

Upscaling AAV gene therapy
Mid-March marks the start of the collaboration of Remedium Bio Inc. and Biovial Oy on an AAV gene therapy for osteoarthritis. Rheumatology and...

Roche withdraws checkpoint blocker from the market
Switzerland’s Hoffmann La Roche AG no longer markets its cancer immunotherapy atezolizumab (Tecentriq) for the treatment of urothelial carcinoma in...

Macomics licences macrophage modulator to Ono
Whether Macomics Ltd nor Ono Pharmaceuticals Co Ltd disclosed any financial details about the deal under which Ono has the option to licence an...

Abivax SA raises €130m to advance obefazimod to Phase III
Existing investors Invus, Deep Track Capital, Sofinnova Partners, Venrock Healthcare Capital Partners, as well as from new investors Great Point...

Minaris and LIfT BioSciences collaborate in cell therapy development
LIfT BioSciences wants to start its first-in-human clinical trials with an allogeneic neutrophil progenitor-based cell therapy in first Quartal...